CIA
UTHR icon

Capital Impact Advisors’s United Therapeutics UTHR Stock Holding History

Capital Impact Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,232
Closed -$6.68M – 37
2025
Q2 		$6.68M Buy
23,232
+2,120
+10% +$634K 2.01% 26
2025
Q1 		$6.51M Buy
+21,112
New +$7.24M 2.49% 25
2024
Q3 		– Sell
-2,996
Closed -$954K – 48
2024
Q2 		$954K Buy
+2,996
New +$793K 2.69% 6
2023
Q3 		– Sell
-3,507
Closed -$774K – 166
2023
Q2 		$774K Buy
+3,507
New +$777K 0.85% 31
2023
Q1 		– Sell
-998
Closed -$278K – 235
2022
Q4 		$278K Hold
998
– – 0.27% 157
2022
Q3 		$209K Sell
998
-244
-20% -$54.5K 0.21% 177
2022
Q2 		$293K Sell
1,242
-1,055
-46% -$214K 0.27% 163
2022
Q1 		$412K Sell
2,297
-5,176
-69% -$986K 0.3% 151
2021
Q4 		$1.61M Sell
7,473
-7,473
-50% -$1.47M 1.11% 32
2021
Q3 		$2.76M Sell
14,946
-2,692
-15% -$530K 1.09% 31
2021
Q2 		$3.16M Hold
17,638
– – 1.02% 35
2021
Q1 		$2.95M Sell
17,638
-1,394
-7% -$232K 1.03% 42
2020
Q4 		$2.89M Sell
19,032
-3,026
-14% -$397K 0.71% 63
2020
Q3 		$2.23M Hold
22,058
– – 0.66% 71
2020
Q2 		$2.67M Sell
22,058
-32,938
-60% -$3.71M 0.89% 46
2020
Q1 		$5.21M Buy
54,996
+3,186
+6% +$303K 2.19% 6
2019
Q4 		$4.56M Hold
51,810
– – 1.61% 8
2019
Q3 		$4.19M Buy
51,810
+22,714
+78% +$1.83M 1.6% 6
2019
Q2 		$2.24M Buy
29,096
+7,394
+34% +$691K 0.82% 34
2019
Q1 		$2.28M Hold
21,702
– – 1.01% 19
2018
Q4 		$2.28M Sell
21,702
-1,823
-8% -$211K 0.97% 20
2018
Q3 		$2.97M Hold
23,525
– – 1.02% 19
2018
Q2 		$2.62M Buy
23,525
+4,319
+22% +$475K 0.97% 20
2018
Q1 		$2.16M Buy
19,206
+3,106
+19% +$395K 0.89% 29
2017
Q4 		$2.38M Hold
16,100
– – 1.03% 19
2017
Q3 		$1.89M Buy
16,100
+996
+7% +$127K 0.84% 32
2017
Q2 		$1.96M Sell
15,104
-1,847
-11% -$230K 0.89% 21
2017
Q1 		$2.29M Sell
16,951
-19,044
-53% -$2.89M 0.91% 15
2016
Q4 		$5.16M Hold
35,995
– – 2.14% 1
2016
Q3 		$4.25M Buy
35,995
+5,900
+20% +$709K 1.84% 1
2016
Q2 		$3.19M Buy
30,095
+23,966
+391% +$2.67M 1.49% 2
2016
Q1 		$683K Buy
6,129
+3,890
+174% +$492K 0.33% 191
2015
Q4 		$351K Hold
2,239
– – 0.17% 232
2015
Q3 		$294K Hold
2,239
– – 0.15% 216
2015
Q2 		$389K Hold
2,239
– – 0.18% 217
2015
Q1 		$386K Sell
2,239
-34,105
-94% -$5.2M 0.18% 218
2014
Q4 		$4.71M Hold
36,344
– – 2.22% 2
2014
Q3 		$2.35M Buy
36,344
+18,253
+101% +$1.88M 3.1% 2
2014
Q2 		$1.6M Hold
18,091
– – 1.21% 17
2014
Q1 		$1.7M Hold
18,091
– – 1.37% 18
2013
Q4 		$2.05M Buy
+18,091
New +$1.63M 1.64% 2

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital Impact Advisors's UTHR Position: Q3 2025 in Review

Capital Impact Advisors sold out of United Therapeutics (UTHR) in Q3 2025, closing a stake of 23,232 shares — an estimated $6.68M sold.

Capital Impact Advisors first reported a position in UTHR in Q4 2013 and held it in 41 quarters. The position peaked at $6.68M in Q2 2025. 707 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

  • Capital Impact Advisors reported no remaining United Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Capital Impact Advisors sold 23,232 United Therapeutics shares in Q3 2025, an estimated $6.68M.
  • Capital Impact Advisors first reported a position in United Therapeutics in Q4 2013 and held it in 41 quarters.
  • Capital Impact Advisors's United Therapeutics position peaked at $6.68M in Q2 2025.
  • 707 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on Capital Impact Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.